FDA Staff Flags Concerns Over Capricor's Duchenne Heart Disease Treatment

Staff at the U.S. Food and Drug Administration (FDA) have raised concerns about a treatment for heart disease associated with Duchenne muscular dystrophy developed by Capricor Therapeutics. According to Reuters, the FDA staff stated in a preliminary review that there are some deficiencies and uncertainties in the data regarding the company's treatment candidate. The FDA staff's assessment has created questions about the efficacy and safety of Capricor's treatment. Specifically, it was noted that data from clinical trials are insufficient and the treatment's effect on cardiac function has not been clearly demonstrated. This could negatively impact the drug's approval process. Capricor is working on a cellular therapy developed to treat heart failure in patients with Duchenne muscular dystrophy. The company had previously stated in announcements that the treatment showed promising results. However, the FDA staff's concerns have drawn investors' attention and caused fluctuations in the company's shares. The FDA is expected to announce its final decision on this treatment in the coming days. Experts suggest that the staff's concerns could delay the approval process or require additional clinical trials. Capricor is expected to collaborate with the FDA to address the deficiencies. This is not investment advice.